Table.

Studies comparing MDRD Study and CKD-EPI equations for long term risk

Author, Date, Study	Population Description, number of participants	Age*	eGFR > 60 ml/min/1.73 m2 (%)	Creatinine assay calibration^	Outcomes	Relative risk in those classified by the CKD-EPI equation to a higher GFR category װ	Relative risk in those classified by the CKD-EPI equation to a lower GFR category װ
McAllister 2012; MAGGIC	Heart failure, n=20,754	68	55	N	All-cause mortality	↓	↑
AlFaleh; 2012; SPACE	Acute coronary syndrome, n =5,034	58	74	N	In-hospital mortality	NR	NR
Skali et al; 2011; VALIANT	AMI with heart failure, n =14,527	66	69	Y	Composite of cardiovascular death, congestive HF, recurrent MI, or stroke	↓	↑
Stevens; 2010 KEEP	High risk, n =116,321	55**	86	Y	All-cause mortality	↓	↑
White; 2010; AusDiab	High risk, n = 11,247	52	93	Y	All-cause mortality	↓	NR
Matsushita; 2010; ARIC	General population, n =13,905	54	98	Y	ESRD, all- cause mortality, coronary heart disease, stroke	↓ for all outcomes	↑ for all outcomes

Studies identified by searching Medline for studies that have compared the CKD-EPI and MDRD Study equations for prognosis

^*Mean or median, as reported in the paper or weighted mean calculated across subgroups

^{^}Assay calibration appropriate for each equation

^װCompared to those not reclassified

^**Mean age from KEEP population reported separately

MAGGIC,Meta-analysis Global Group in Chronic Heart Failure; SPACE; The Saudi Project for Assessment of Coronary Events; VALIANT; Valsartan in Acute Myocardial Infarction Trial; AMI, Acute Myocardial Infarction; KEEP, Kidney Early Evaluation Program; AusDiab; Australian Diabetes, Obesity and Life Style Study Survey; ARIC Atherosclerosis Risk in Communities; ESRD, End Stage Renal Disease; N, no; Y, yes; NR, Not Reported;